tradingkey.logo
tradingkey.logo
Search

Ligand Pharmaceuticals Inc

LGND
Add to Watchlist
280.900USD
-3.570-1.25%
Close 09-11 16:00ET
5.60BMarket Cap
36.61P/E TTM

Ligand Pharmaceuticals Inc (LGND) Revenue Performance

Updated: Jun 30, 2026

By Business

Annual
Annual
Quarterly
Contract Revenue- Other
Captisol
Kyprolis
Filspari
Qarziba
Rylaze
Royalties Other
Capvaxive
Ohtuvayre
Teriparatide injection
Vaxneuvance
Evomela
Royalty asset-Other
Milestone
Rylaze
Service Revenue
Teriparatide injection
License Fees
Promacta
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Contract Revenue- Other
66.87M(24.94%)
1.94M(1.16%)
1.40M(1.07%)
6.11M(3.11%)
6.41M(2.31%)
4.97M(2.66%)
12.17M(10.12%)
Captisol
40.21M(15.00%)
30.88M(18.48%)
28.37M(21.61%)
104.50M(53.25%)
164.25M(59.27%)
109.96M(58.98%)
31.49M(26.18%)
Kyprolis
35.53M(13.25%)
38.38M(22.96%)
35.64M(27.14%)
30.12M(15.35%)
27.47M(9.91%)
25.16M(13.50%)
25.05M(20.82%)
Filspari
31.97M(11.93%)
12.18M(7.29%)
--(--)
--(--)
--(--)
--(--)
--(--)
Qarziba
23.74M(8.85%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Rylaze
13.35M(4.98%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Royalties Other
10.37M(3.87%)
8.95M(5.35%)
13.48M(10.26%)
7.63M(3.89%)
11.38M(4.10%)
2.25M(1.21%)
2.57M(2.13%)
Capvaxive
10.06M(3.75%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Ohtuvayre
9.76M(3.64%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Teriparatide injection
8.15M(3.04%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Vaxneuvance
7.40M(2.76%)
5.18M(3.10%)
--(--)
--(--)
--(--)
--(--)
--(--)
Evomela
5.94M(2.22%)
8.68M(5.19%)
10.21M(7.78%)
10.20M(5.20%)
10.08M(3.64%)
6.38M(3.42%)
5.17M(4.30%)
Royalty asset-Other
4.73M(1.76%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Milestone
--(--)
25.53M(15.28%)
16.80M(12.79%)
9.15M(4.66%)
28.75M(10.37%)
11.52M(6.18%)
23.45M(19.50%)
Rylaze
--(--)
13.74M(8.22%)
13.52M(10.30%)
8.80M(4.48%)
--(--)
--(--)
--(--)
Service Revenue
--(--)
13.44M(8.04%)
615.00K(0.47%)
1.12M(0.57%)
23.71M(8.56%)
21.80M(11.70%)
--(--)
Teriparatide injection
--(--)
8.22M(4.92%)
11.06M(8.42%)
15.79M(8.04%)
--(--)
--(--)
--(--)
License Fees
--(--)
--(--)
217.00K(0.17%)
2.85M(1.45%)
5.08M(1.83%)
4.38M(2.35%)
6.20M(5.15%)
Promacta
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
14.19M(11.80%)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.